Drugs that contain Suvorexant
1. Belsomra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7951797 | MERCK SHARP DOHME | Substituted diazepan orexin receptor antagonists |
Nov, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-253) | Jan 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2019 |
NCE-1 date: 13 August, 2018
Market Authorisation Date: 13 August, 2014
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
More Information on Dosage
BELSOMRA family patents
